Jay Edelberg from Sanofi: Praluent Continues to Show Benefits Since Approval
At the 2015 meeting of the American College of Cardiology PCSK9 inhibitors like Praluent were moving closer to approval but were not there yet. Since then they have been approved and begun to be introduced to the public.
At the 2015 meeting of the American College of Cardiology (ACC) PCSK9 inhibitors like Praluent were moving closer to approval but were not there yet. Since then they have been approved and begun to be introduced to the public.
Jay Edelberg, MD, PhD, from Sanofi discussed how things have changed for the medication over the course of the year and what the future is during the 2016 meeting of the ACC in Chicago.
Related Videos
Related Content
